The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.

NowDx's First to Know Syphilis Test received FDA authorization in August, making it the first over-the-counter syphilis test to be authorized by the agency.

The San Francisco-based firm will use the proceeds to accelerate commercialization of its Intellisep rapid sepsis test.

Deck: Xgenera has also closed a round of seed financing worth £500,000 and commenced a partnership with YouSeq, a UK technology firm.

The governmental funding will support the company's plans for a 1,350 participant trial that aims to further validate its protein-based cancer early detection assay.